Bae SC, et al. - This meta-analysis was conducted in rheumatoid arthritis (RA) patients with an inadequate methotrexate (MTX) or tumor necrosis factor (TNF) inhibitors response in order to evaluate the relative effectiveness and tolerability of tocilizumab, sarilumab, and sirukumab. Tocilizumab 8 mg as a monotherapy and combined with MTX, illustrated acceptable tolerability and the highest performance based on the ACR50 response rate, followed by sarilumab and sirukumab, in the study cohort.